Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 146

1.

Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes.

Grasedieck S, Mulaw M, Sperb N, Wessinger K, Rouhi A, Bommer M, Bromberg JEC, Otto M, Tumani H, von Arnim CAF, Mertens D, Kuchenbauer F.

Neuropathol Appl Neurobiol. 2018 Apr 21. doi: 10.1111/nan.12491. [Epub ahead of print] No abstract available.

PMID:
29679382
2.

Intrathecal immunoglobulin M production: A promising high-risk marker in clinically isolated syndrome patients.

Huss A, Abdelhak A, Halbgebauer S, Mayer B, Senel M, Otto M, Tumani H.

Ann Neurol. 2018 May;83(5):1032-1036. doi: 10.1002/ana.25237. Epub 2018 May 11.

PMID:
29665046
3.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
4.

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.

Teunissen CE, Otto M, Engelborghs S, Herukka SK, Lehmann S, Lewczuk P, Lleó A, Perret-Liaudet A, Tumani H, Turner MR, Verbeek MM, Wiltfang J, Zetterberg H, Parnetti L, Blennow K.

Alzheimers Res Ther. 2018 Mar 15;10(1):30. doi: 10.1186/s13195-018-0359-x. Review.

5.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

6.

Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay.

Carcamo Yañez VA, Göpfert JC, Otto M, Tumani H, Peter A, Joos TO.

High Throughput. 2017 Nov 16;6(4). pii: E18. doi: 10.3390/ht6040018.

7.

Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression.

Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, Foerstl H, Giese A, Jahn H, Kassubek J, Kornhuber J, Landwehrmeyer GB, Lauer M, Pinkhardt EH, Prudlo J, Rosenbohm A, Schneider A, Schroeter ML, Tumani H, von Arnim CAF, Weishaupt J, Weydt P, Ludolph AC, Yilmazer Hanke D, Otto M; FTLDc study group.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):239-247. doi: 10.1136/jnnp-2017-317138. Epub 2017 Nov 15.

PMID:
29142138
8.

Preface.

Deisenhammer F, Teunissen CE, Tumani H.

Handb Clin Neurol. 2017;146:ix. doi: 10.1016/B978-0-12-804279-3.09987-1. No abstract available.

PMID:
29110783
9.

Epilepsy.

Fauser S, Tumani H.

Handb Clin Neurol. 2017;146:259-266. doi: 10.1016/B978-0-12-804279-3.00015-0. Review.

PMID:
29110774
10.

The cerebrospinal fluid and barriers - anatomic and physiologic considerations.

Tumani H, Huss A, Bachhuber F.

Handb Clin Neurol. 2017;146:21-32. doi: 10.1016/B978-0-12-804279-3.00002-2. Review.

PMID:
29110772
11.

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.

Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.

J Neuroinflammation. 2017 Aug 31;14(1):172. doi: 10.1186/s12974-017-0945-z.

12.

GFAP in early multiple sclerosis: A biomarker for inflammation.

Kassubek R, Gorges M, Schocke M, Hagenston VAM, Huss A, Ludolph AC, Kassubek J, Tumani H.

Neurosci Lett. 2017 Sep 14;657:166-170. doi: 10.1016/j.neulet.2017.07.050. Epub 2017 Aug 9.

PMID:
28802830
13.

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.

Abdelhak A, Hottenrott T, Mayer C, Hintereder G, Zettl UK, Stich O, Tumani H.

PLoS One. 2017 Aug 10;12(8):e0182647. doi: 10.1371/journal.pone.0182647. eCollection 2017.

14.

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle.

Abdelhak A, Weber MS, Tumani H.

Front Neurol. 2017 May 31;8:234. doi: 10.3389/fneur.2017.00234. eCollection 2017. Review.

15.

Consensus guidelines for lumbar puncture in patients with neurological diseases.

Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE.

Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007. eCollection 2017.

16.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

17.

Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression.

Hesse R, Lausser L, Gummert P, Schmid F, Wahler A, Schnack C, Kroker KS, Otto M, Tumani H, Kestler HA, Rosenbrock H, von Arnim CA.

Alzheimers Res Ther. 2017 Mar 9;9(1):17. doi: 10.1186/s13195-017-0245-y.

18.

Gain-of-function STAT1 mutations are associated with intracranial aneurysms.

Dadak M, Jacobs R, Skuljec J, Jirmo AC, Yildiz Ö, Donnerstag F, Baerlecken NT, Schmidt RE, Lanfermann H, Skripuletz T, Schwenkenbecher P, Kleinschnitz C, Tumani H, Stangel M, Pul R.

Clin Immunol. 2017 May;178:79-85. doi: 10.1016/j.clim.2017.01.012. Epub 2017 Feb 2.

PMID:
28161409
19.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

20.

Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders.

Jordan W, Dobrowolny H, Bahn S, Bernstein HG, Brigadski T, Frodl T, Isermann B, Lessmann V, Pilz J, Rodenbeck A, Schiltz K, Schwedhelm E, Tumani H, Wiltfang J, Guest PC, Steiner J.

Eur Arch Psychiatry Clin Neurosci. 2018 Mar;268(2):129-143. doi: 10.1007/s00406-016-0749-7. Epub 2016 Dec 2.

PMID:
27913877

Supplemental Content

Loading ...
Support Center